This Key Event Relationship is licensed under the Creative Commons BY-SA license. This license allows reusers to distribute, remix, adapt, and build upon the material in any medium or format, so long as attribution is given to the creator. The license allows for commercial use. If you remix, adapt, or build upon the material, you must license the modified material under identical terms.
Relationship: 3518
Title
Decreased, 17βHSD3 activity leads to Decrease, circulating testosterone levels
Upstream event
Downstream event
Key Event Relationship Overview
AOPs Referencing Relationship
Taxonomic Applicability
Term | Scientific Term | Evidence | Link |
---|---|---|---|
mammals | mammals | High | NCBI |
Sex Applicability
Sex | Evidence |
---|---|
Mixed | Moderate |
Life Stage Applicability
Term | Evidence |
---|---|
All life stages | High |
Key Event Relationship Description
17-beta-HSD3 is a hydroxysteroid (17-beta) dehydrogenase with its 17-ketosteroid reductase activity that catalyses the conversion of androstenedione into testosterone with NADPH as a cofactor. It is expressed mainly in the testes and to a lesser extent in the brain and adipose tissue (Corbould et al., 2002; Mindnich et al., 2004; Payne & Hales, 2004).
An inhibition of 17-beta-HSD3 would lead to less conversion of androstenedione to testosterone and therefore a decrease in testosterone levels.
Evidence Collection Strategy
The KER describes a generally recognized and understood process, i.e. canonical knowledge. The aim of the literature search was therefore to identify review articles and book chapters that summarise the canonical knowledge. PubMed was searched using key words related to steroidogenesis. The search was restricted to reviews from the last 10 years.
Evidence Supporting this KER
Biological Plausibility
Conversion from the less potent androgen, androstenedione, to testosterone is known to be performed by the enzymatic activity of 17-beta-HSD3. This reaction is essential for testosterone synthesis in testis (Mindnich et al., 2004; Payne & Hales, 2004). This is reflected in deficiencies of 17-beta-HSD3, which is the most common deficiency when it comes to issues with androgen synthesis. This deficiency usually results in disorder of sexual development (DSD). Patients with mutations in this enzyme have higher levels of circulating androstenedione, lower levels of testosterone, and present with ambiguous poorly masculinized genitalia (Bertelloni et al., 2009; Lawrence et al., 2022).
Empirical Evidence
Several chemicals have been designed to inhibit the activity of 17-beta-HSD3, usually to be used to treat prostate cancer as the enzyme is overexpressed leading to increased T levels and increased proliferation of prostate cancer cells (Marchais-Oberwinkler et al., 2011).
Uncertainties and Inconsistencies
A knockout mouse study has raised concerns regarding the difference between species. It shows that even when 17-beta-HSD3 is knocked out, male mice can maintain intratesticular levels of testosterone and are fertile with correct spermatogenesis. This shows that there may be another enzyme responsible for synthesis of testosterone in mice when 17-beta-HSD3 is not present (Lawrence et al., 2022).
Known modulating factors
Quantitative Understanding of the Linkage
Response-response Relationship
Time-scale
Known Feedforward/Feedback loops influencing this KER
Domain of Applicability
Taxonomic applicability
Although testosterone and 17-beta-HSD3 is important for other vertebrates, this KER focuses on mammals (Mindnich et al., 2004).
Life stage applicability
Finally, it has been shown that the role of 17-beta-HSD3 in catalysing the synthesis of testosterone occurs throughout all life stages (Mindnich et al., 2004).
Sex applicability
This KER is applicable to males and females as 17-beta-HSD3 is expressed in both. However, it seems more essential to male testicular testosterone synthesis as shown by the effect of 17-beta-HSD3 deficiencies observed mainly in men (Bertelloni et al., 2009; Corbould et al., 2002).
References
Bertelloni, S., Dati, E., & Hiort, O. (2009). Diagnosis of 17β-hydroxysteroid dehydrogenase deficiency. Expert Review of Endocrinology & Metabolism, 4(1), 53–65. https://doi.org/10.1586/17446651.4.1.53
Corbould, A., Bawden, M., Lavranos, T., Rodgers, R., & Judd, S. (2002). The effect of obesity on the ratio of type 3 17β-hydroxysteroid dehydrogenase mRNA to cytochrome P450 aromatase mRNA in subcutaneous abdominal and intra-abdominal adipose tissue of women. International Journal of Obesity, 26(2), 165–175. https://doi.org/10.1038/sj.ijo.0801886
Lawrence, B. M., O’Donnell, L., Smith, L. B., & Rebourcet, D. (2022). New Insights into Testosterone Biosynthesis: Novel Observations from HSD17B3 Deficient Mice. International Journal of Molecular Sciences, 23(24), 15555. https://doi.org/10.3390/ijms232415555
Marchais-Oberwinkler, S., Henn, C., Möller, G., Klein, T., Negri, M., Oster, A., Spadaro, A., Werth, R., Wetzel, M., Xu, K., Frotscher, M., Hartmann, R. W., & Adamski, J. (2011). 17β-Hydroxysteroid dehydrogenases (17β-HSDs) as therapeutic targets: Protein structures, functions, and recent progress in inhibitor development. The Journal of Steroid Biochemistry and Molecular Biology, 125(1–2), 66–82. https://doi.org/10.1016/j.jsbmb.2010.12.013
Mindnich, R., Möller, G., & Adamski, J. (2004). The role of 17 beta-hydroxysteroid dehydrogenases. Molecular and Cellular Endocrinology, 218(1–2), 7–20. https://doi.org/10.1016/j.mce.2003.12.006
Payne, A. H., & Hales, D. B. (2004). Overview of Steroidogenic Enzymes in the Pathway from Cholesterol to Active Steroid Hormones. Endocrine Reviews, 25(6), 947–970. https://doi.org/10.1210/er.2003-0030